HRP20131069T1 - Derivati kinoksalindiona - Google Patents
Derivati kinoksalindiona Download PDFInfo
- Publication number
- HRP20131069T1 HRP20131069T1 HRP20131069AT HRP20131069T HRP20131069T1 HR P20131069 T1 HRP20131069 T1 HR P20131069T1 HR P20131069A T HRP20131069A T HR P20131069AT HR P20131069 T HRP20131069 T HR P20131069T HR P20131069 T1 HRP20131069 T1 HR P20131069T1
- Authority
- HR
- Croatia
- Prior art keywords
- dione
- dihydroquinoxaline
- hydroxy
- stereoisomers
- dihydro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (4)
1. Spoj naznačen time da je odabran iz skupine koja sadrži
ester 2,3-diokso-1,2,3,4-tetrahidro-kinoksalin-5-il octene kiseline,
5-hidroksi-4-metil-1,4-dihidrokinoksalin-2,3-dion,
5-hidroksi-1,4-dimetil-1,4-dihidrokinoksalin-2,3-dion,
1,4-dimetil-5-metoksi-1,4-dihidrokinoksalin-2,3-dion,
ester 2,3-diokso-1,2,3,4-tetrahidro-kinoksalin-5-il 2,2-dimetil-propionske kiseline,
8-metoksi-1-metil-1,4-dihidro-kinoksalin-2,3-dion,
4,6-dihidro-1H-pirido[3,4-b]pirazin-2,3,5-trion,
8-hidroksi-1,4-dihidro-pirido[2,3-b]pirazin-2,3-dion,
5-metoksi-1-metil-1,4-dihidrokinoksalin-2,3-dion,
5-hidroksi-1-metil-1,4-dihidrokinoksalin-2,3-dion,
5-(2-hidroksi-etoksi)-1,4-dihidro-kinoksalin-2,3-dion,
i njihove farmaceutski korisne soli i stereoizomeri, uključujući njihove smjese u svim omjerima.
2. Medikamenti naznačeni time da sadrže barem jedan spoj prema zahtjevu 1, i/ili njihove farmaceutski korisne soli i stereoizomeri, uključujući njihove smjese u svim omjerima, te proizvoljno pomoćne tvari i/ili adjuvante.
3. Uporaba spojeva prema zahtjevu 1, i njihovih farmaceutski korisnih soli i stereoizomera, uključujući njihove smjese u svim omjerima, naznačena time da je za dobivanje medikamenta za liječenje metaboličkog sindroma, dijabetesa, pretilosti, raka, upale, kardiovaskularnih bolesti.
4. Uporaba spojeva prema zahtjevu 1 i njihovih farmaceutski korisnih derivata, soli, solvata i stereoizomera, uključujući njihove smjese u svim omjerima, naznačena time da je za dobivanje medikamenta za liječenje metaboličkog sindroma, dijabetesa, pretilosti.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08290564 | 2008-06-16 | ||
| PCT/EP2009/003538 WO2009152909A1 (en) | 2008-06-16 | 2009-05-19 | Quinoxalinedione derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20131069T1 true HRP20131069T1 (hr) | 2013-12-20 |
Family
ID=40823394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20131069AT HRP20131069T1 (hr) | 2008-06-16 | 2009-05-19 | Derivati kinoksalindiona |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8329698B2 (hr) |
| EP (1) | EP2285786B1 (hr) |
| JP (1) | JP5596676B2 (hr) |
| KR (1) | KR101641391B1 (hr) |
| CN (1) | CN102066342B (hr) |
| AR (1) | AR072148A1 (hr) |
| AU (1) | AU2009259754B2 (hr) |
| BR (1) | BRPI0915064B8 (hr) |
| CA (1) | CA2728018C (hr) |
| CO (1) | CO6321252A2 (hr) |
| CY (1) | CY1114737T1 (hr) |
| DK (1) | DK2285786T3 (hr) |
| EA (1) | EA020236B1 (hr) |
| EC (1) | ECSP11010760A (hr) |
| ES (1) | ES2436195T3 (hr) |
| HR (1) | HRP20131069T1 (hr) |
| IL (1) | IL209421A (hr) |
| MX (1) | MX2010013577A (hr) |
| MY (1) | MY155695A (hr) |
| NZ (1) | NZ590503A (hr) |
| PL (1) | PL2285786T3 (hr) |
| PT (1) | PT2285786E (hr) |
| SI (1) | SI2285786T1 (hr) |
| WO (1) | WO2009152909A1 (hr) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| SI3459942T1 (sl) | 2012-04-24 | 2021-05-31 | Vertex Pharmaceuticals Incorporated | Inhibitorji DNA-PK |
| HUE041544T2 (hu) | 2013-03-12 | 2019-05-28 | Vertex Pharma | DNS-PK inhibitorok |
| EP2970177A1 (en) | 2013-03-15 | 2016-01-20 | Pfizer Inc. | Indole compounds that activate ampk |
| CN103435561B (zh) * | 2013-08-19 | 2016-08-10 | 上海交通大学 | 一种新型d-氨基酸氧化酶抑制剂及其制备和应用 |
| PT3424920T (pt) | 2013-10-17 | 2020-07-07 | Vertex Pharma | Co-cristais de (s)-n-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propan-2-il)quinolina-4-carboxamida e derivados deuterados dos mesmos como inibidores de adn-pk |
| JP2019529475A (ja) | 2016-09-27 | 2019-10-17 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ｄｎａ損傷剤とｄｎａ−ｐｋ阻害剤との組合せ物を使用する、がんを処置するための方法 |
| US20220152117A1 (en) * | 2019-03-18 | 2022-05-19 | University Of Washington | Methods of promoting cellular maturation with ampk activators |
| CN110642798B (zh) * | 2019-11-10 | 2020-07-24 | 湖南科技学院 | 一种n-取代-1,4-二氢-2,3-喹喔啉二酮化合物的绿色合成方法 |
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| CN116323608A (zh) | 2020-05-19 | 2023-06-23 | 卡尔优普公司 | Ampk活化剂 |
| EP4172162A4 (en) | 2020-06-26 | 2024-08-07 | Kallyope, Inc. | AMPK ACTIVATORS |
| WO2022072397A1 (en) | 2020-09-30 | 2022-04-07 | Bioverativ Therapeutics Inc. | Ampk activators and methods of use thereof |
| WO2022072783A1 (en) | 2020-10-02 | 2022-04-07 | Incyte Corporation | Bicyclic dione compounds as inhibitors of kras |
| CN116615199A (zh) * | 2020-11-26 | 2023-08-18 | 株式会社Lg化学 | 作为二酰基甘油激酶抑制剂的杂环化合物及其用途 |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| US12404348B2 (en) | 2021-11-19 | 2025-09-02 | The Brigham And Women's Hospital, Inc. | Bifunctional chimeric molecules for labeling of kinases with target binding moieties and methods of use thereof |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5631373A (en) | 1993-11-05 | 1997-05-20 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon | Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones |
| CA2278757A1 (en) | 1997-02-18 | 1998-08-20 | Uresh Shantilal Shah | 5-aminoalkoxy-1,4-dihydroquinoxaline-2,3-diones being dopamine agonists |
| JP2004538267A (ja) | 2001-05-25 | 2004-12-24 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 閉塞性気道疾患及びその他の炎症性疾患を治療するためのドーパミンｄ２−受容体アゴニスト及びチオトロピウム又はその誘導体の組み合わせ |
| CA2551639A1 (en) * | 2004-01-06 | 2005-07-28 | Janssen Pharmaceutica N.V. | (3-oxo-3, 4-dihydro-quinoxalin-2-yl-amino) -benzamide derivatives and related compound as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity |
| MY139645A (en) * | 2004-02-11 | 2009-10-30 | Amgen Inc | Vanilloid receptor ligands and their use in treatments |
| MX2008014618A (es) * | 2006-05-15 | 2008-11-28 | Irm Llc | Composiciones y metodos para inhibidores de cinasas del receptor fgf. |
| FR2903695B1 (fr) * | 2006-07-13 | 2008-10-24 | Merck Sante Soc Par Actions Si | Utilisation de derives d'imidazole activateurs de l'ampk, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2009
- 2009-05-19 BR BRPI0915064A patent/BRPI0915064B8/pt not_active IP Right Cessation
- 2009-05-19 SI SI200930812T patent/SI2285786T1/sl unknown
- 2009-05-19 US US12/997,641 patent/US8329698B2/en not_active Expired - Fee Related
- 2009-05-19 CN CN2009801227397A patent/CN102066342B/zh not_active Expired - Fee Related
- 2009-05-19 PL PL09765489T patent/PL2285786T3/pl unknown
- 2009-05-19 MY MYPI2010005917A patent/MY155695A/en unknown
- 2009-05-19 KR KR1020117000992A patent/KR101641391B1/ko not_active Expired - Fee Related
- 2009-05-19 EP EP09765489.1A patent/EP2285786B1/en active Active
- 2009-05-19 ES ES09765489T patent/ES2436195T3/es active Active
- 2009-05-19 EA EA201100007A patent/EA020236B1/ru not_active IP Right Cessation
- 2009-05-19 CA CA2728018A patent/CA2728018C/en active Active
- 2009-05-19 DK DK09765489.1T patent/DK2285786T3/da active
- 2009-05-19 WO PCT/EP2009/003538 patent/WO2009152909A1/en not_active Ceased
- 2009-05-19 MX MX2010013577A patent/MX2010013577A/es active IP Right Grant
- 2009-05-19 PT PT97654891T patent/PT2285786E/pt unknown
- 2009-05-19 AU AU2009259754A patent/AU2009259754B2/en not_active Ceased
- 2009-05-19 JP JP2011513895A patent/JP5596676B2/ja not_active Expired - Fee Related
- 2009-05-19 HR HRP20131069AT patent/HRP20131069T1/hr unknown
- 2009-05-19 NZ NZ590503A patent/NZ590503A/xx not_active IP Right Cessation
- 2009-06-16 AR ARP090102166A patent/AR072148A1/es active IP Right Grant
-
2010
- 2010-11-18 IL IL209421A patent/IL209421A/en active IP Right Grant
- 2010-12-14 CO CO10156748A patent/CO6321252A2/es active IP Right Grant
-
2011
- 2011-01-14 EC EC2011010760A patent/ECSP11010760A/es unknown
-
2012
- 2012-08-24 US US13/593,722 patent/US8674097B2/en not_active Expired - Fee Related
-
2013
- 2013-12-27 CY CY20131101166T patent/CY1114737T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2020000062A (es) | Procedimiento para la preparación de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato de metilo y su purificación para el uso como principio activo farmacéutico | |
| MX2010006438A (es) | Derivados de tetrahidro-imidazo [1,5-a] pirazina proceso de preparacion y su uso medicinal. | |
| EP4349839A3 (en) | Tricyclic akr1c3 dependent kars inhibitors | |
| EA200870592A1 (ru) | Триазолопиразиновые соединения, пригодные для лечения дегенеративных и воспалительных заболеваний | |
| WO2010054113A3 (en) | Cycloalkane[b]azaindole antagonists of prostaglandin d2 receptors | |
| CA2824432C (en) | Aerosol pirfenidone and pyridone analog compounds and uses thereof | |
| EA201400392A1 (ru) | ПРОИЗВОДНЫЕ 6-ЗАМЕЩЕННЫХ ТРИАЗОЛОПИРИДАЗИНОВ КАК АГОНИСТЫ Rev-Erb | |
| WO2011085643A8 (zh) | 吡啶并环衍生物 | |
| DOP2010000165A (es) | 4-(4-ciano-2-tioaril) dihidropirimidinonas y su uso como inhibidores de la elastasa neutrofila humana | |
| WO2008035359A3 (en) | Oximinophenoxyalkanoic acid and phenylalkanoic acid derivatives | |
| WO2007144327A3 (en) | Phenyl-pyrazole derivatives as non-steroidal glucocoricoid receptor ligands | |
| WO2009125434A3 (en) | Oxime derivatives, process for their preparation, pharmaceutical composition containing the same and medicinal use thereof | |
| MY155695A (en) | Quinoxalinedione derivatives | |
| WO2009030952A3 (en) | Phenylcarboxamide derivatives as inhibitors and effectors of the hedgehog pathway | |
| WO2007062186A3 (en) | Methods of using small molecule compounds for neuroprotection | |
| EA032938B1 (ru) | Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения | |
| WO2008093075A3 (en) | 5,6,7,8-tetrahydropteridine derivatives as hsp90 inhibitors | |
| CL2014002097A1 (es) | Compuestos derivados de tetrahidro-quinazolinona, inhibidores de tank y parp-1; proceso de preparacion; medicamentos; kit farmaceutico; uso en el tratamiento y/o la prevencion de cancer, esclerosis multiple, enfermedades cardiovasculares, lesion del sistema nervioso central. | |
| WO2018067520A2 (en) | Therapeutic agents and methods: | |
| CR11823A (es) | Compuestos de pirazina fusionados utiles para el tratamiento de enfermedades degenarativas e inflamatorias | |
| JP2007238598A5 (hr) | ||
| JP2016515550A5 (hr) | ||
| WO2014068463A3 (en) | Compositions and methods for the treatment of inflammation and metabolic disorders | |
| KR20120131183A (ko) | 악액질 치료용 그렐린 수용체 작용제 | |
| WO2010044097A3 (en) | Novel dosage form of paliperidone and process for preparing the same |